NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

Pagon RA, Adam MP, Ardinger HH, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2016.

Cover of GeneReviews®

GeneReviews® [Internet].

Show details


Synonym: Louis-Bar Syndrome
, MD
Department of Pathology
David Geffen School of Medicine at UCLA
Los Angeles, California

Initial Posting: ; Last Update: March 11, 2010.


Clinical characteristics.

Classic ataxia-telangiectasia (A-T) is characterized by progressive cerebellar ataxia beginning between ages one and four years, oculomotor apraxia, choreoathetosis, telangiectasias of the conjunctivae, immunodeficiency, frequent infections, and an increased risk for malignancy, particularly leukemia and lymphoma. Individuals with A-T are unusually sensitive to ionizing radiation. Non-classic forms of A-T have included adult-onset A-T and A-T with early-onset dystonia.


Diagnosis of A-T relies on clinical findings, including slurred speech, truncal ataxia, and oculomotor apraxia; neuroimaging; and family history. Laboratory findings that support the diagnosis include: severely depleted levels of intracellular ATM protein, elevated serum alpha-fetoprotein concentration; 7;14 chromosome translocation on chromosome analysis of peripheral blood; immunodeficiency; and radiosensitivity demonstrated by in vitro assay. ATM is the only gene known to be associated with A-T.


Treatment of manifestations: IVIG replacement therapy for individuals with frequent and severe infections and low IgG levels; aggressive pulmonary hygiene for those with chronic bronchiectasis; supportive therapy for drooling, choreoathetosis, and ataxia.

Prevention of secondary complications: Early and continued physical therapy to minimize contractures and scoliosis.

Surveillance: Monitoring for early signs of malignancy (e.g., weight loss, bruising, localized pain or swelling). Monitoring of immune status in those with severe recurrent infections or undergoing immunomodulatory therapy.

Agents/circumstances to avoid: Excessive ionizing radiation including those from diagnostic procedures such as repeated or high resolution CT scans; attention to risks associated with general anesthesia.

Other: Children under age five years with malignancy should be evaluated for A-T before starting chemotherapy and radiotherapy since conventional doses of either can be fatal in A-T. Although use of steroids can temporarily improve neurologic symptoms in children with A-T, the symptoms reappear within days of steroid discontinuation.

Genetic counseling.

A-T is inherited in an autosomal recessive manner. At conception, the sibs of an affected individual have a 25% chance of being affected, a 50% chance of being asymptomatic carriers, and a 25% chance of being unaffected and not carriers. ATM heterozygotes (carriers) may have an increased risk of developing cancer. Carrier testing for at-risk relatives and prenatal testing for pregnancies at increased risk are possible if the pathogenic variants in the family are known.


Clinical Diagnosis

Ataxia-telangiectasia (A-T) is suspected in children who show progressive cerebellar dysfunction between ages one and four years. This can present as:

  • Gait and truncal ataxia
  • Head tilting
  • Slurred speech
  • Oculomotor apraxia and uneven (interrupted or “bumpy”) tracking across a visual field

A small cerebellum, often observed on MRI, is not usually apparent in young children.


Serum concentration of alpha-fetoprotein (AFP). Serum AFP concentration is elevated above 10 ng/mL in more than 95% of individuals with A-T.

Note: Serum AFP concentration may remain above normal in unaffected children until age 24 months.

Immunoblotting for ATM protein. Intracellular ATM protein is severely depleted in most patients with A-T. To date, this is the most sensitive and specific clinical test for establishing a diagnosis of A-T. Small amounts of ATM protein have been occasionally associated with a milder prognosis, although there are many exceptions to this and the association needs further validation.

Of individuals with A-T:

  • About 90% have no detectable ATM protein.
  • About 10% have trace amounts of ATM protein.
  • About 1% have a normal amount of ATM protein that lacks ATM serine/threonine kinase activity (so-called "kinase-dead").

Note: Immunoblotting assays are not easily quantified and thus the determination of "trace amounts" and "undetectable amounts" of ATM protein often overlap. The results of immunoblotting are influenced by the following:

  • The amount of cell lysate loaded. Optimal results are obtained by loading nuclear lysate prepared from at least five million cells, or 25 μg of lysate protein [Chun et al 2003]. This is most reliably achieved by first establishing a lymphoblastoid cell line (LCL) on each test sample [Author, personal observation], a procedure requiring a minimum of four to six weeks;
  • The titer of the developing antibody to ATM;
  • The time and method of exposure of the autoradiogram;
  • The technique used to compare the band density of observed ATM protein;
  • The range of sensitivity of the radiographic film or chemiluminescence reader.

Butch et al [2004] described a rapid immunoassay to measure ATM protein that is both sensitive and specific for the diagnosis of A-T. Note: This method requires a reliable and renewable source of purified ATM protein [Chun et al 2004] and requires that a daily control be included to insure that a result of ‘very low ATM protein’ is not caused by poor specimen handling.

ATM-dependent phosphorylation of ATM substrates. Recent reports describe rapid flow cytometric methods that measure ATM-dependent phosphorylation of ATM substrates, such as ATM itself [Porcedda et al 2008], H2AX (encoded by H2AFX ) [Honda et al 2009], and SMC1 [Nahas et al 2009]. Studies comparing this method to ATM immunoblotting remain to be completed.

Radiosensitivity assay. The colony survival assay (CSA) is an in vitro assay that determines the survival of patient-derived lymphoblastoid cells following irradiation with 1.0 Gy [Sun et al 2002]. The CSA was abnormal in 103 of 104 individuals (99%) who had at least one identifiable ATM pathogenic variant; however, seven of 104 individuals scored in an intermediate radiosensitivity range that overlaps with the normal range [Sun et al 2002].

Note: (1) Exposure of the lymphoblastoid cells of such individuals to several radiation doses (1.0, 1.5, and 2.0 Gy) can produce a dose-response curve. (2) The test takes approximately three months to complete. Dose-response testing requires additional time.

ATM serine/threonine kinase activity. The serine/threonine kinase activity of ATM protein can be assessed using immunoblotting of cell lysates and commercial antibodies to many phosphorylated ATM target substrates. Frequently used substrates include p53-serine15 (encoded by TP53), ATM-serine1981, KAP1 (encoded by TRIM28) and SMC1-serine966 (encoded by SMC1A). Cells are first irradiated to create double-strand DNA breaks which activate ATM serine/threonine kinase. If evaluated within 30 minutes after irradiation, ATM serine/threonine kinase activity is undetectable in all situations in which ATM protein levels are undetectable.

Note: (1) Cell lysates prepared from patient-derived cell lines established for immunoblot testing for ATM protein or for the radiosensitivity assay are also used to evaluate ATM protein serine/threonine kinase activity [Chun et al 2003, Nahas et al 2005]. (2) Although ATM serine/threonine kinase activity is difficult to quantify, as a quantitative assay, the kinase activity constitutes a very important test for evaluating ATM function and identifies rare individuals with A-T with normal or near-normal amounts of ATM protein that lacks kinase function.

In individuals with ‘kinase-dead’ ATM protein (such as when associated with the c.7271T>G pathogenic variant) ATM serine/threonine kinase activity is markedly reduced [Stewart et al 2001].

Chromosome analysis. A 7;14 chromosome translocation is identified in 5%-15% of cells in routine chromosomal studies of peripheral blood of individuals with A-T in which lymphocytes have been stimulated with phytohemagglutinin (PHA) and harvested at 72 hours. The break points are commonly at 14q11 (the T-cell receptor-alpha locus) and at 14q32 (the B-cell receptor [IGH] locus).

Note: Routine karyotyping may be difficult in individuals with A-T because lymphocytes are decreased in number and do not respond well to PHA, resulting in ‘no metaphases observed.’ The difficulty may be partially overcome by adding more PHA and harvesting the cells at 72 hours instead of 48 hours. Unless interpreted by an experienced cytogeneticist, routing karyotyping is unreliable for diagnosing A-T and is superfluous to molecular testing.

Heterozygotes (carriers). The new FC-pSMC1 assay utilizes flow cytometry to measure the intranuclear phosphorylation of SMC1 protein (encoded by SMC1A). This assay reports a clear distinction of ATM heterozygotes from normal individuals and homozygotes [Nahas et al 2009].

Molecular Genetic Testing

Gene. ATM is the only gene known to be associated with ataxia-telangiectasia. More than 99% of individuals with classic A-T have pathogenic variants in ATM.

Clinical testing

Sequence analysis. Sequence analysis of the ATM coding region detects about 90% of ATM sequence variants; however, the functional consequences of variants are often very difficult to interpret. Sequencing may be performed on genomic DNA or cDNA made from mRNA purified from a lymphoblastoid cell line of the patient; the latter is less costly but not always available. In general, DNA sequencing for diagnosis of A-T is of lower sensitivity than immunoblotting and is several times more expensive. Furthermore, intronic pathogenic variants and heterozygous deletions of an exon(s) or whole gene are not detected.

Note: The author has experience with one or two individuals in whom neither pathogenic variant can be identified despite the absence of ATM protein [Author, personal observation]. It is estimated that about 10% of persons with A-T have only one ATM pathogenic variant identified using sequence analysis [Author, personal observation]; however, these data are no longer of publication interest and thus cannot be confirmed.

Deletion/duplication analysis

  • Of the 600 unique pathogenic variants reported, approximately 14 ‘large genomic deletions’ have been described. By convention, these are genomic deletions larger than 500 bp and not those involving single exons only.
  • Only one partial (41-kb) duplication within ATM has been described to date [Cavalieri et al 2006, Cavalieri et al 2008].

It is unknown how many affected individuals in whom only one ATM pathogenic variant has been identified by sequence analysis have actually been tested for deletions or duplications by either chromosomal microarray (CMA) or multiplex ligation-dependent probe amplification (MLPA).

Targeted analysis for pathogenic variants is offered for pathogenic alleles common in specific ethnic populations (e.g., c.103C>T).

Linkage analysis/ethnic haplotype analysis. Linkage analysis involves testing DNA sequence polymorphisms (benign variants such as short tandem repeats, [STR]) that are near or within a gene of interest in order to track within a family the inheritance of a pathogenic variant in the given gene. In specific well-studied ethnic groups (e.g., Amish, Mennonite, Costa Rican, Spanish, Brazilian, Polish, British, Russian, Italian, Turkish, Iranian, Israeli), STR analysis at 11q23.1 can be used to rapidly identify founder haplotypes that are in linkage disequilibrium with known or unknown pathogenic variants [Campbell et al 2003, Mitui et al 2003, Coutinho et al 2004]. See Table 2. For previously identified variants, direct sequencing from DNA is possible.

Table 1.

Summary of Molecular Genetic Testing Used in Ataxia-Telangiectasia

Gene 1Test MethodAllelic Variants Detected 2Variant Detection Frequency by Test Method 3
ATMSequence analysis gDNASequence variants 4~90%
Sequence analysis cDNA 5Sequence variants 4~95% 6
Deletion/duplication analysis 7Large genomic deletionsPerhaps 1%-2%
Targeted analysis for pathogenic variantsc.103C>T>99% for the c.103C>T variant
Linkage analysis / ethnic haplotype analysisSee footnote 8(not applicable)

See Molecular Genetics for information on allelic variants.


The ability of the test method used to detect a variant that is present in the indicated gene


Examples of pathogenic variants detected by sequence analysis may include small intragenic deletions/insertions and missense, nonsense, and splice site variants; typically, exon or whole-gene deletions/duplications are not detected. For issues to consider in interpretation of sequence analysis results, click here.


cDNA scanning by PCR amplification of large segments, followed by sequence confirmation on cDNA and then gDNA. By first scanning cDNA, it is possible to not only detect but to identify the ‘consequences’ of splicing variants.


Detection frequencies are for the detection of at least one mutant allele per haplotype.


Testing that identifies deletions/duplications not readily detectable by sequence analysis of the coding and flanking intronic regions of genomic DNA; included in the variety of methods that may be used are: quantitative PCR, long-range PCR, multiplex ligation-dependent probe amplification (MLPA), and chromosomal microarray (CMA) that includes this gene/chromosome segment.


A pathogenic variant is not detected directly.

Interpretation of test results. Significant difficulties exist in distinguishing polymorphisms from pathogenic missense variants [Richards et al 2008, Mitui et al 2009, Tavtigian et al 2009].

Testing Strategy

To establish the diagnosis in a proband


Assay of ATM protein level. If the ATM protein level by immunoblotting is:

  • Absent or seen only in trace amounts, a diagnosis of A-T is made.
  • Greater than trace amounts and the radiosensitivity is normal, a diagnosis of A-T is usually excluded.
  • Normal and the radiosensitivity assay is abnormal, the ATM serine/threonine kinase activity is tested to determine if a non-functional (kinase-dead) ATM protein is present (<1% of individuals with A-T).

Note: The radiosensitivity assay is also informative for identifying those individuals who do not have A-T but may have another DNA repair disorder.

2. Molecular genetic testing of ATM to identify both pathogenic variants

Carrier testing for at-risk relatives presently requires prior identification of the pathogenic variants in the family. Nahas et al [2009] described a new rapid method for carrier detection using functional flow cytometry.

Note: Carriers are heterozygotes for this autosomal recessive disorder. Heterozygotes are not at increased risk of developing A-T neurologic manifestations, but are at a fourfold increased risk of developing breast cancer through mechanisms that are not understood [Gatti et al 1999, Scott et al 2002].

Prenatal diagnosis and preimplantation genetic diagnosis (PGD) for at-risk pregnancies require a firm laboratory diagnosis of a prior affected family member and either prior identification of the pathogenic variants in the family or haplotyping with short tandem repeat (STR) markers if the proband is available to identify the affected haplotype or the haplotype has been previously identified through family studies.

Clinical Characteristics

Clinical Description

Classic Ataxia-Telangiectasia

The primary features of classic A-T include progressive gait and truncal ataxia with onset between ages one and four years, progressively slurred speech, oculomotor apraxia (inability to follow an object across visual fields), choreoathetosis (writhing movements); oculocutaneous telangiectasia (usually evident by age 6 years); frequent infections (with accompanying evidence of serum and cellular immunodeficiencies); and hypersensitivity to ionizing radiation with increased susceptibility to cancer (usually leukemia or lymphoma).

Other features include premature aging with strands of gray hair and endocrine abnormalities, such as insulin-resistent diabetes mellitus.

The A-T syndrome varies little from family to family in its late stages. For clinical reviews, see Boder [1985], Gatti [2002], Perlman et al [2003], Chun & Gatti [2004], Nowak-Wegrzyn et al [2004], and Taylor & Byrd [2005]. However, the time of onset and rate of progression of symptoms can vary considerably even in a family with multiple affected individuals.

Cerebellar ataxia. The most obvious and troubling characteristic of classic A-T is the progressive cerebellar ataxia. Shortly after learning to walk, children with A-T begin to stagger. The neurologic status of some children appears to improve from age two to four years, then ataxia begins to progress again; the transient improvement is probably attributable to the rapid learning curve of young children. The ataxia begins as purely truncal but within several years involves peripheral coordination as well. By age ten years, most children become confined to a wheelchair for the remainder of their lives.

Slurred speech and oculomotor apraxia are noted early. Both horizontal and vertical saccadic eye movements are affected [Lewis et al 1999, Farr et al 2002, Onodera 2006, Yakusheva et al 2007].

Choreoathetosis is found in almost all individuals with A-T. Myoclonic jerking and intention tremors are present in about 25% of individuals.

Deep tendon reflexes are decreased or absent in older individuals; plantar reflexes are upgoing or absent. Three siblings with A-T presented with lower motor neuron degeneration [Larnaout et al 1998].

Drooling is common.

Writing is affected by age seven or eight years.

All teenagers with classic A-T need help with dressing, eating, washing, and using the toilet. Because swallowing is not well coordinated, eating should be slow and deliberate to avoid aspirating food [Lefton-Greif et al 2000]. Muscle strength is normal at first but wanes with disuse, especially in the legs. Contractures in the fingers and toes are common in older individuals but may be minimized by rigorous exercise.

Intelligence is typically normal; however, learning difficulties are common. Slow motor and verbal responses make it difficult for individuals to complete timed IQ tests. Many American and British individuals with classic A-T have finished high school with good grades; some have finished college or university.

Immunodeficiency. Immunodeficiencies are present in 60% to 80% of individuals with classic A-T; they are variable and do not correlate well with the frequency, severity or spectrum of infections. The immunodeficiency is not progressive [Boder 1985, Woods & Taylor 1992, Gatti 2002, Nowak-Wegrzyn et al 2004, Pashankar et al 2006].

The most consistent immunodeficiency reported in classic A-T is poor antibody response to pneumococcal polysaccharide vaccines [Sanal et al 1999, Nowak-Wegrzyn et al 2004]. Serum concentration of the immunoglobulins IgA, IgE, and IgG2 may be reduced. Approximately 30% of individuals with classic A-T who have immunodeficiency have T-cell deficiencies. At autopsy, virtually all individuals have a small embryonic-like thymus.

Infection. In contrast to the spectrum of infection in most immunodeficiency disorders, the spectrum of infection in classic A-T does not include opportunistic infections. Some individuals with classic A-T develop chronic bronchiectasis. The frequency and severity of infections correlates more with general nutritional status than with the immune status. Although individuals with frequent and severe classic A-T infections appear to occasionally benefit from intravenous immunoglobulin (IVIG) replacement therapy [Nowak-Wegrzyn et al 2004], longevity has increased substantially even in affected individuals not receiving IVIG.

Cancer risk. The risk for malignancy in individuals with classic A-T is 38%. Leukemia and lymphoma account for about 85% of malignancies. Younger children tend to have acute lymphocytic leukemia (ALL) of T-cell origin and older children are likely to have an aggressive T-cell leukemia. Lymphomas are usually B-cell types. As individuals with classic A-T are living longer, other cancers and tumors, including ovarian cancer, breast cancer, gastric cancer, melanoma, leiomyomas, and sarcomas, have also been observed.

Life span. Over the past 20 years, the expected life span of individuals with A-T has increased considerably; most affected individuals now live beyond age 25 years. Some have survived into their 50s [Dörk et al 2004, Crawford et al 2006]. In older individuals, pulmonary failure, with or without identifiable infections, is a major cause of failing health and death. Life-threatening lymphocytic infiltration of the lung has been reported [Tangsinmankong et al 2001].

Pathology. The cerebellum atrophies early in the course of classic A-T, being visibly smaller on MRI examination by age seven or eight years, with concomitant loss of Purkinje cells and depletion of granule cells [Sardanelli et al 1995, Tavani et al 2003, Lin et al 2006, Wallis et al 2007].

Microscopic nucleomegaly also occurs in the cells of tissues throughout the body.

Non-Classic Forms of Ataxia-Telangiectasia

Phenotypes other than classic A-T associated with homozygosity or compound heterozygosity for two deleterious ATM variants include:

Heterozygotes. The cancer risk of individuals heterozygous for ATM pathogenic variants is approximately four times that of the general population, primarily because of the increased risk for breast cancer [Swift et al 1991, Stankovic et al 1998, Geoffroy-Perez et al 2001, Olsen et al 2001, Teraoka et al 2001, Sommer et al 2002, Bernstein et al 2003, Bretsky et al 2003, Sommer et al 2003, Thorstenson et al 2003, Ahmed & Rahman 2006, Bernstein et al 2006, Einarsdóttir et al 2006, Renwick et al 2006, Pylkäs et al 2007, Concannon et al 2008].

ATM variants have been reported in both tumor cells and germline cells in several forms of leukemia and lymphoma, including acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), T-cell prolymphocytic leukemia (T-PLL), and mantle zone lymphoma [Stankovic et al 1998, Stilgenbauer et al 2000, Fang et al 2003, Oguchi et al 2003, Yamaguchi et al 2003, Eclache et al 2004].

Cancer risk probably depends on multiple factors including tumor type, age at cancer onset, and whether the heterozygote carries a missense or a truncating pathogenic variant [Gatti et al 2001, Concannon 2002, Scott et al 2002, Spring et al 2002].

  • Breast cancer-associated ATM pathogenic variants tend to be missense whereas missense variants are uncommon in individuals with A-T, even in the same host population [Bernstein et al 2003].
  • T-cell ALL-associated ATM pathogenic variants are similar to those seen in individuals with A-T [Liberzon et al 2004, Pylkäs et al 2007].

Epidemiologic studies suggest that A-T carriers are also at an increased risk for heart disease [Swift 1985, Swift et al 1991].

Genotype-Phenotype Correlations

A pathogenic variant commonly referred to as 5762ins137 is associated with a somewhat slower rate of neurologic deterioration, later onset of symptoms, intermediate radiosensitivity, and little or no cancer risk [McConville et al 1996]. This variant is formally designated as c.5762-1050A>G [Sutton et al 2004].

The pathogenic variants c.7271T>G, c.8147T>C, and c.8494C>T have been associated with a milder phenotype and longer life span [Stankovic et al 1998, Verhagen et al 2009]. However, the limited number of individuals with these variants and the lack of individuals homozygous for the variants preclude making statistically significant correlations.


A-T complementation groups (A-E) were defined when fibroblasts (from different individuals with A-T) that fused to form heterodikaryons did not complement the radiosensitive phenotype of any other A-T cells as assayed in several laboratories by several different methods. Later, groups A and B were thought to be the same (i.e., group AB) and together they accounted for more than half of the families tested worldwide.

Complementation group Variant 1 of A-T (V1) included individuals with Nijmegen breakage syndrome (NBS), a rather different phenotype, now known to be caused by mutation of NBS1. NBS was named Variant 1 of A-T because the cellular phenotype and chromosome abnormalities observed were similar to those of A-T.

Complementation group Variant 2 of A-T (V2) included individuals with Berlin breakage syndrome (BBS), a phenotype similar to NBS, now known to be caused by mutation of NBS1 [Gatti 2002].

ATFresno was considered yet another clinical variant of A-T, and in limited studies appeared to complement group V1 cells [Gatti 1991]. It is now known that ATFresno is caused by mutation of ATM [Gilad et al 1998, Chun et al 2004].

Because NBS and BBS resemble A-T in various ways, use of the term ‘AT-like disorder’ (ATLD) has appeared often in the old and new literature.

More recently, the term AT-like disorder was used to describe a form of ataxia associated with Mre11 deficiency [Stewart et al 1999], which is more appropriately designated as Mre11-deficient ataxia. The Mre11 protein is encoded by MRE11A. Use of the latter term avoids confusion, not only for Mre11-deficient ataxia but for other A-T-like phenotypes that are neither A-T nor Mre11 deficiency [Bakheet et al 2008].


The prevalence of A-T in the US is 1:40,000-1:100,000 live births.

A-T is the most common cause of progressive cerebellar ataxia in childhood in most countries; ataxia with oculomotor apraxia (AOA) may be more prevalent in Portugal and perhaps Japan [Németh et al 2000, Date et al 2001, Moreira et al 2001]. (See Ataxia with Oculomotor Apraxia Type 1 and Ataxia with Oculomotor Apraxia Type 2.)

Prevalence varies with the degree of consanguinity in a country.

Differential Diagnosis

Establishing the diagnosis of ataxia-telangiectasia is most difficult in very young children, primarily because all characteristic features are not yet present.

The most common misdiagnosis is cerebral palsy.

The diagnosis of A-T is questionable when accompanied by severe intellectual disability, seizures, non-progressive ataxia, or microcephaly.

Other disorders with childhood-onset ataxia are discussed in the Ataxia Overview.

A-T-like disorders to consider in the differential diagnosis include:

Lymphoblastoid cells from individuals with Friedreich ataxia, ataxia with oculomotor apraxia type 1 (AOA1), and ataxia with oculomotor apraxia type 2 (AOA2) are not typically radiosensitive by CSA [Németh et al 2000, Moreira et al 2001, Nahas et al 2007]. Thus, CSA can be used to distinguish these disorders from A-T.

Although radiosensitivity, as measured by CSA, is often used in the diagnosis of A-T, radiosensitivity is also seen in Nijmegen breakage syndrome; RAD50 deficiency; X-linked agammaglobulinemia; Fanconi anemia syndrome [Sun et al 2002, Nahas et al 2005, Waltes et al 2009]; ligase IV deficiency [O'Driscoll et al 2001]; and severe combined immunodeficiency with Cernunnos, Artemis deficiency, DNA-PKcs deficiency, or RNF168 deficiency [Buck et al 2006a, Buck et al 2006b, Gatti et al 2007, Stewart et al 2007, Stewart et al 2009, van der Burg et al 2009]. Although none of these disorders is characterized by ataxia or elevated serum concentration of AFP, two individuals with RNF168 deficiency have recently been described with a syndrome that includes mild ataxia and elevated serum concentration of alphafetoprotein. The diagnosis of this disorder can be established by identification of microscopic 53BP1 irradiation-induced nuclear foci [Devgan et al 2011].


Evaluations Following Initial Diagnosis

To establish the extent of disease in an individual diagnosed with ataxia-telangiectasia (A-T), the following evaluations are recommended:

  • Serum alpha-fetoprotein (AFP)
  • MRI of cerebellum
  • Chest x-ray and pulmonary function for baseline
  • Neurologic consultation, including ocular coordination
  • Karyotype for characteristic t7;14 translocations and leukemic clones
  • CBC with differential as baseline for screening for leukemia
  • Diabetes screen (urinalysis, fasting blood glucose concentration, Hgb A1C)
  • Immune work-up (Immunoglobulin levels, B/T cell levels, T cell function)
  • Immunoblot for approximate level of ATM protein in nuclear lysates and as an aid in prognosis, family counseling, and possible later therapy

Note: Liver enzyme levels are often elevated in A-T, without apparent liver pathology. Liver biopsy is usually not necessary.

Treatment of Manifestations

IVIG replacement therapy should be considered for individuals with frequent and severe infections and very low IgG levels [Nowak-Wegrzyn et al 2004].

Individuals with chronic bronchiectasis require aggressive pulmonary hygiene. However, these therapeutic attempts are often to no avail in the final stages of the disease [Tangsinmankong et al 2001].

Supportive therapy is available to minimize drooling, choreoathetosis, and ataxia; individual responses to specific medications vary [Perlman et al 2003].

A wheelchair is usually necessary by age ten years.

Although steroids can temporarily improve the neurologic symptoms of A-T in children, the symptoms reappear within days of their discontinuation [Gatti 1985, Buoni et al 2006, Broccoletti et al 2008, Gatti & Perlman 2009].

Prevention of Secondary Complications

Early and continued physical therapy minimizes contractures, which appear in almost all individuals with time and lead to other physical problems.

Prolonged time in a wheelchair, especially the tendency to lean on the same elbow, can produce serious scoliosis, which can be mitigated by aggressive physical therapy.


Parents should be counseled to monitor for and report to a physician the early warning signs of malignancy (which can occur at any age), such as weight loss, bruising, and localized pain or swelling.

Immune status needs to be monitored if severe recurrent infections occur or immunomodulatory therapy is in progress.

Agents/Circumstances to Avoid

Because cells from individuals with A-T are 30% more sensitive to ionizing radiation than cells from controls, conventional doses are potentially lethal in individuals with A-T and the use of radiotherapy and some radiomimetic chemotherapeutic agents in treatment should be monitored carefully. Doses of some chemotherapeutic agents are often reduced by 25%-50% and longer recovery periods between treatments are considered to allow for the slower DNA repair that occurs in these individuals. Before finalizing a therapeutic protocol for cancer in individuals with A-T, the A-T professional community recommends a consultation with St. Jude’s Hospital, Department of Oncology [Lavin et al 1999].

Anesthesia carries unique risks in persons with A-T because of the impaired coordination of swallowing, the increased risk of aspiration, the reduced respiratory capacity, and the propensity to infections [McGrath-Morrow et al 2008].

Evaluation of Relatives at Risk

See Genetic Counseling for issues related to testing of at-risk relatives for genetic counseling purposes.

Therapies Under Investigation

New research suggests the following:

  • Iron chelators, such as the antioxidant epigallocatechin-3-gallate (EGCG), improve genomic stability of atm-deficient mice [Shackelford et al 2004].
  • Although N-acetyl cysteine has also been reported to be effective in atm-deficient mice [Reliene & Schiestl 2006], an informal clinical trial in patients with A-T showed no improvement [Author, unpublished].
  • Antioxidants (e.g., vitamin E or alpha-lipoic acid) are recommended, although no formal testing for efficacy has been conducted in individuals with A-T. Alpha-lipoic acid has the theoretical advantage of crossing the blood-brain barrier and improving mitochondrial function in A-T cells [Ambrose et al 2007].
  • Maganese-containing superoxide dismutase mimics have a radioprotective effect on A-T cells [Pollard et al 2009].
  • In culture, aminoglycoside antibiotics can induce small amounts of full-length ATM protein and return of ATM functions to A-T cells with pathogenic nonsense variants [Lai et al 2004]. Non-aminoglycoside readthrough chemicals also induce ATM protein in A-T cells [Du & Gatti 2009].
  • Antisense morpholino oligonucleotides (AMOs) induce substantial corrections of ATM protein in patients with certain types of ATM splicing variants [Du et al 2007, Du et al 2009]. AMOs remain active in A-T cells for more than 14 days. In animal studies, they are well tolerated when a cell-penetrating protein (CPP) moiety is added to the AMO.
  • Betamethasone, but not methylprednisilone, has been reported to decrease neurologic symptoms [Buoni et al 2006, Broccoletti et al 2008]. However, the neurologic improvement, which is accompanied by signs of steroid toxicity, disappears within days of discontinuation of the steroids. Additional studies are in progress [Gatti 1985, Gatti & Perlman 2009].

Use of insulin-like growth factor 1 treatment for A-T has been suggested [Fernandez et al 2005].

Recent efforts at pathogenic variant-targeted therapy have been encouraging [Du et al 2009]. Thus, identifying ATM pathogenic variants may provide new therapeutic opportunities in the near future [Bedwell et al 1997, Wilschanski et al 2003, Lai et al 2004, Du et al 2007, Welch et al 2007, Hu & Gatti 2008, Du & Gatti 2009].

Search for access to information on clinical studies for a wide range of diseases and conditions.


Any child under age five years with malignancy should be evaluated for A-T before starting chemotherapy and/or radiotherapy since conventional doses of either can be fatal in A-T.

Genetic Counseling

Genetic counseling is the process of providing individuals and families with information on the nature, inheritance, and implications of genetic disorders to help them make informed medical and personal decisions. The following section deals with genetic risk assessment and the use of family history and genetic testing to clarify genetic status for family members. This section is not meant to address all personal, cultural, or ethical issues that individuals may face or to substitute for consultation with a genetics professional. —ED.

Mode of Inheritance

Ataxia-telangiectasia is inherited an autosomal recessive manner.

Risk to Family Members

Parents of a proband

Sibs of a proband

  • At conception, each sib of an affected individual has a 25% risk of being affected, a 50% risk of being an asymptomatic carrier, and a 25% risk of being unaffected and not a carrier.
  • Once an at-risk sib is known to be unaffected, the risk of his/her being a carrier is 2/3.

Offspring of a proband. Most individuals with A-T do not reproduce.

Other family members of a proband. Each sib of the proband's parents is at a 50% risk of being a carrier.

Carrier Detection

Carrier testing is possible if the pathogenic variants in the family have been identified. This can also be accomplished by linkage analysis (i.e., segregation of affected haplotypes) if an affected family member has also been haplotyped.

Related Genetic Counseling Issues

Family planning. The optimal time for determination of genetic risk, clarification of carrier status, and discussion of the availability of prenatal testing is before pregnancy.

DNA banking is the storage of DNA (typically extracted from white blood cells) for possible future use. Because it is likely that testing methodology and our understanding of genes, allelic variants, and diseases will improve in the future, consideration should be given to banking DNA of affected individuals.

Prenatal Testing

If the pathogenic variants have been identified or linkage has been established in the family, prenatal diagnosis for pregnancies at increased risk may be available from a clinical laboratory offering either testing for the gene/disease or custom testing.

Prenatal diagnosis by chromosome breakage studies or by radio-resistent DNA synthesis (RDS) has proven unreliable in at least three instances [Author, unpublished] and should be avoided in favor of molecular genetic testing approaches.

Preimplantation genetic diagnosis (PGD) may be an option for some families in which the pathogenic variants have been identified.


GeneReviews staff has selected the following disease-specific and/or umbrella support organizations and/or registries for the benefit of individuals with this disorder and their families. GeneReviews is not responsible for the information provided by other organizations. For information on selection criteria, click here.

  • A-T Children's Project
    5300 West Hillsboro Boulevard
    Coconut Creek FL 33073
    Phone: 800-543-5728 (toll-free); 954-481-6611
    Fax: 954-725-1153
  • A-T Medical Research Foundation
    16224 Elisa Place
    Encino CA 91436
    Phone: 818-906 2861
    Fax: 818-906-2870
  • National Cancer Institute (NCI)
    6116 Executive Boulevard
    Suite 300
    Bethesda MD 20892-8322
    Phone: 800-422-6237 (toll-free)
  • National Library of Medicine Genetics Home Reference
  • NCBI Genes and Disease
  • National Ataxia Foundation
    2600 Fernbrook Lane
    Suite 119
    Minneapolis MN 55447
    Phone: 763-553-0020
  • European Society for Immunodeficiencies (ESID) Registry
    Dr. Gerhard Kindle
    University Medical Center Freiburg Centre of Chronic Immunodeficiency
    Engesserstr. 4
    79106 Freiburg
    Phone: 49-761-270-34450
  • Prospective Registry of MultiPlex Testing (PROMPT)
    PROMPT is an online research registry for patients and families who have undergone multiplex genetic testing and were found to have a genetic variation which may be linked to an increased risk of having cancer.

Molecular Genetics

Information in the Molecular Genetics and OMIM tables may differ from that elsewhere in the GeneReview: tables may contain more recent information. —ED.

Table A.

Ataxia-Telangiectasia: Genes and Databases

Data are compiled from the following standard references: gene from HGNC; chromosome locus, locus name, critical region, complementation group from OMIM; protein from UniProt. For a description of databases (Locus Specific, HGMD) to which links are provided, click here.

Table B.

OMIM Entries for Ataxia-Telangiectasia (View All in OMIM)


Gene structure. The normal gene has 66 (62 coding) exons and a 13-kb cDNA. For a detailed summary of gene and protein information, see Table A, Gene.

Pathogenic allelic variants. More than 500 unique pathogenic variants are known (see Table 2 and Table 3). No common variants (‘hot spots’) have been identified. Most affected individuals in North America inherit different pathogenic variants from each parent, i.e., they are compound heterozygotes [Concannon & Gatti 1997, Gatti et al 2001]. Most pathogenic variants result in absence of ATM protein.

Table 2.

Selected ATM Pathogenic Variants

DNA Nucleotide Change
(Alias 1)
Protein Amino Acid ChangeReference Sequences
c.8147T>Cp.Val2716Ala 2
See footnote 3

Note on variant classification: Variants listed in the table have been provided by the author. GeneReviews staff have not independently verified the classification of variants.

Note on nomenclature: GeneReviews follows the standard naming conventions of the Human Genome Variation Society (www​ See Quick Reference for an explanation of nomenclature.


Variant designation that does not conform to current naming conventions


Activates a cryptic splice site resulting in a 137-bp insertion and a truncated protein [McConville et al 1996, Stewart et al 2001, Sutton et al 2004]

Founder variants have been described in many populations (Table 3).

Table 3.

ATM Pathogenic Variants in Ethnic Populations

EthnicityDNA Nucleotide Change
(Alias 1)
Protein Amino Acid ChangeAllele Frequency (%)
African Americanc.2851-10T>G
Costa Ricanc.5908C>Tp.Gln1970Ter56
c.3576G>A(Deletion of exon 26)12
p.Ser131PhefsTer3Sardinia (>95%)
North African Jewishc.103C>Tp.Arg35Ter>99
Norwegianc.3245_3247delATC insTGAT
(IVS53-2A>C(del159nt)) 2
c.6095G>A(Deletion of exon 43)8
p.Glu1978Ter10 3
See Table 218 4
p.Arg2547_Ser2549del15 5
Utah Mormonc.5395-12A>G

See Table 2 for reference sequences.


Variant designation that does not conform to current naming conventions


Also found in Mennonite and Russian persons with A-T


Milder phenotype?


Widely disseminated

Normal gene product. The normal serine-protein kinase ATM has 3056 amino acids. It senses double-stranded DNA breaks, coordinates cell-cycle checkpoints prior to repair, attaches near damage sites, and recruits other repair proteins to damaged sites [Lavin 2008].

  • Domains for: PI3 kinase, FAT, leucine zipper, FATC, p53 binding
  • Binding sites for: c-abl, p53, Bloom’s protein
  • Other homologies: DNA-PK, ATR/MEC1, MEI41, Rad3, TEL1, FRAP
  • Substrates for phosphorylation: >700, including p53, Chk2, MDM2, 53BP1, SMC1, BRCA1, FANCD2, H2AX, c-abl, nibrin, Mre11, KAP1 [Linding et al 2007, Matsuoka et al 2007].

Abnormal gene product. Serine-protein kinase ATM is absent on immunoblotting in 95% of individuals. ATM mRNA is present in more than 99% of affected individuals; however, the quantity of mRNA from each mutant allele may not be equal. About 1% of individuals with A-T have variants that permit normal expression of ATM protein, but the protein is lacking in kinase activity (so-called ‘Kinase-dead’ ATM protein). In vitro functional assays showed that selected pathogenic missense variants result in an ATM protein that interferes with the function of normal ATM protein (i.e., a dominant negative effect) [Barone et al 2009]. It has been proposed that such effects play a role in the development of breast cancer in ATM heterozygotes [Scott et al 2002].


Literature Cited

  1. Ahmed M, Rahman N. ATM and breast cancer susceptibility. Oncogene. 2006;25:5906–11. [PubMed: 16998505]
  2. Alterman N, Fattal-Valevski A, Moyal L, Crawford TO, Lederman HM, Ziv Y, Shiloh Y. Ataxia-telangiectasia: mild neurological presentation despite null ATM mutation and severe cellular phenotype. Am J Med Genet A. 2007;143A:1827–34. [PubMed: 17632790]
  3. Ambrose M, Goldstine JV, Gatti RA. Intrinsic mitochondrial dysfunction in ATM-deficient lymphoblastoid cells. Hum Mol Genet. 2007;16:2154–64. [PubMed: 17606465]
  4. Bakheet DM, Al Tassan NA, Al Sharif LJ, Khalil DS, Al Khairallah TS, Bohlega SA. Molecular characterization of ataxia oculomotor apraxia in Saudi Arabia. Poster session. Philadelphia, PA: 58th Annual Meeting of the American Society of Human Genetics. 2008.
  5. Barone G, Groom A, Reiman A, Srinivasan V, Byrd PJ, Taylor AM. Modeling ATM mutant proteins from missense changes confirms retained kinase activity. Hum Mut. 2009;30:1222–30. [PubMed: 19431188]
  6. Bedwell DM, Kaenjak A, Benos DJ, Bebok Z, Bubien JK, Hong J, Tousson A, Clancy JP, Sorscher EJ. Suppression of a CFTR premature stop mutation in a bronchial epithelial cell line. Nat Med. 1997;3:1280–4. [PubMed: 9359706]
  7. Bernstein JL, Teraoka S, Haile RW, Borresen-Dale AL, Rosenstein BS, Gatti RA, Diep AT, Jansen L, Atencio DP, Olsen JH, Bernstein L, Teitelbaum SL, Thompson WD, Concannon P. Designing and implementing quality control for multi-center screening of mutations in the ATM gene among women with breast cancer. Hum Mutat. 2003;21:542–50. [PubMed: 12673797]
  8. Bernstein JL, Teraoka S, Southey MC, Jenkins MA, Andrulis IL, Knight JA, John EM, Lapinski R, Wolitzer AL, Whittemore AS, West D, Seminara D, Olson ER, Spurdle AB, Chenevix-Trench G, Giles GG, Hopper JL. Concannon P. Population-based estimates of breast cancer risks associated with ATM gene variants c.7271T>G and c.1066-6T>G (IVS10-6T>G) from the Breast Cancer Family Registry. Hum Mutat. 2006;27:1122–8. [PubMed: 16958054]
  9. Bodensteiner JB, Goldlum RM, Goldman AS. Professive dystonia masking ataxia in ataxia-telangiectasia. Arch Neurol. 1980;37:464–5. [PubMed: 7387499]
  10. Boder E. Ataxia-telangiectasia: an overview. In: RA Gatti, M Swift, eds. Ataxia-Telangiectasia: Genetics, Neuropathy, and Immunology of a Degenerative Disease of Childhood. New York, NY: Alan R Liss; 1985:1-63.
  11. Bretsky P, Haiman CA, Gilad S, Yahalom J, Grossman A, Paglin S, Van Den Berg D, Kolonel LN, Skaliter R, Henderson BE. The relationship between twenty missense ATM variants and breast cancer risk: the Multiethnic Cohort. Cancer Epidemiol Biomarkers Prev. 2003;12:733–8. [PubMed: 12917204]
  12. Broccoletti T, Del Giudice E, Amorosi S, Russo I, Di Bonito M, Imperati F, Romano A, Pignata C. Steroid-induced improvement of neurological signs in ataxia-telangiectasia patients. Eur J Neurol. 2008;15:223–8. [PubMed: 18290844]
  13. Buck D, Malivert L, de Chasseval R, Barraud A, Fondanèche MC, Sanal O, Plebani A, Stéphan JL, Hufnagel M, le Deist F, Fischer A, Durandy A, de Villartay JP, Revy P. Cernunnos, a novel nonhomologous end-joining factor, is mutated in human immunodeficiency with microcephaly. Cell. 2006a;124:287–99. [PubMed: 16439204]
  14. Buck D, Moshous D, De Chasseval R, Ma Y, le Deist F, Cavazzana-Calvo M, Fischer A, Casanova JL, Lieber MR, de Villartay JP. Severe combined immunodeficiency and microcephaly in siblings with hypomorphic mutations in DNA ligase IV. Eur J Immunol. 2006b;36:224–35. [PubMed: 16358361]
  15. Buoni S, Zannolli R, Sorrentino L, Fois A. Betamethasone and improvement of neurological symptoms in ataxia-telangiectasia. Arch Neurol. 2006;63:1479–82. [PubMed: 17030666]
  16. Butch AW, Chun HH, Nahas SA, Gatti RA. Immunoassay to measure ataxia-telangiectasia mutated protein in cellular lysates. Clin Chem. 2004;50:2302–8. [PubMed: 15486025]
  17. Campbell C, Mitui M, Eng L, Coutinho G, Thorstenson Y, Gatti RA. ATM mutations on distinct SNP and STR haplotypes in ataxia-telangiectasia patients of differing ethnicities reveal ancestral founder effects. Hum Mutat. 2003;21:80–5. [PubMed: 12497634]
  18. Cavalieri S, Funaro A, Pappi P, Migone N, Gatti RA, Brusco A. Large genomic mutations within the ATM gene detected by MLPA, including a duplication of 41 kb from exon 4 to 20. Ann Hum Genet. 2008;72:10–8. [PubMed: 17910737]
  19. Cavalieri S, Funaro A, Porcedda P, Turinetto V, Migone N, Gatti RA, Brusco A. ATM mutations in Italian families with ataxia telangiectasia include two distinct large genomic deletions. Hum Mutat. 2006;27:1061. [PubMed: 16941484]
  20. Chun HH, Gatti RA. Ataxia-telangiectasia, an evolving phenotype. DNA Repair (Amst) 2004;3:1187–96. [PubMed: 15279807]
  21. Chun HH, Cary RB, Lansigan F, Whitelegge J, Rawlings DJ, Gatti RA. ATM protein purified from vaccinia virus expression system: DNA binding requirements for kinase activation. Biochem Biophys Res Commun. 2004;322:74–81. [PubMed: 15313175]
  22. Chun HH, Sun X, Nahas SA, Teraoka S, Lai CH, Concannon P, Gatti RA. Improved diagnostic testing for ataxia-telangiectasia by immunoblotting of nuclear lysates for ATM protein expression. Mol Genet Metab. 2003;80:437–43. [PubMed: 14654357]
  23. Concannon P. ATM heterozygosity and cancer risk. Nat Genet. 2002;32:89–90. [PubMed: 12205473]
  24. Concannon P, Gatti RA. Diversity of ATM gene mutations detected in patients with ataxia-telangiectasia. Hum Mutat. 1997;10:100–7. [PubMed: 9259193]
  25. Concannon P, Haile RW, Børresen-Dale AL, Rosenstein BS, Gatti RA, Teraoka SN, Diep TA, Jansen L, Atencio DP, Langholz B, Capanu M, Liang X, Begg CB, Thomas DC, Bernstein L, Olsen JH, Malone KE, Lynch CF, Anton-Culver H, Bernstein JL., Women's Environment, Cancer, and Radiation Epidemiology Study Collaborative Group. Variants in the ATM gene associated with a reduced risk of contralateral breast cancer. Cancer Res. 2008;68:6486–91. [PMC free article: PMC2562548] [PubMed: 18701470]
  26. Coutinho G, Mitui M, Campbell C, Costa Carvalho BT, Nahas S, Sun X, Huo Y, Lai CH, Thorstenson Y, Tanouye R, Raskin S, Kim CA, Llerena J Jr, Gatti RA. Five haplotypes account for fifty-five percent of ATM mutations in Brazilian patients with ataxia telangiectasia: seven new mutations. Am J Med Genet A. 2004;126A:33–40. [PubMed: 15039971]
  27. Crawford TO, Skolasky R, Fernandez R, Rosquist KJ, Lederman HM. Survival probability in ataxia Telangiectasia. Arch Dis Child. 2006;91:610–11. [PMC free article: PMC2082822] [PubMed: 16790721]
  28. Curry CJ, O'Lague P, Tsai J, Hutchison HT, Jaspers NG, Wara D, Gatti RA, Hutchinson HT. ATFresno: a phenotype linking ataxia-telangiectasia with the Nijmegen breakage syndrome. Am J Hum Genet. 1989;45:270–5. [PMC free article: PMC1683342] [PubMed: 2491181]
  29. Date H, Onodera O, Tanaka H, Iwabuchi K, Uekawa K, Igarashi S, Koike R, Hiroi T, Yuasa T, Awaya Y, Sakai T, Takahashi T, Nagatomo H, Sekijima Y, Kawachi I, Takiyama Y, Nishizawa M, Fukuhara N, Saito K, Sugano S, Tsuji S. Early-onset ataxia with ocular motor apraxia and hypoalbuminemia is caused by mutations in a new HIT superfamily gene. Nat Genet. 2001;29:184–8. [PubMed: 11586299]
  30. Devgan SS, Sanal O, Doil C, Nakamura K, Nahas SA, Pettijohn K, Bartek J, Lukas C, Lukas J, Gatti RA. Homozygous deficiency of ubiquitin-ligase ring-finger protein RNF168 mimics the radiosensitivity syndrome of ataxia-telangiectasia. Cell Death Differ. 2011;18:1500–6. [PMC free article: PMC3178430] [PubMed: 21394101]
  31. Dörk T, Bendix-Waltes R, Wegner RD, Stumm M. Slow progression of ataxia-telangiectasia with double missense and in frame splice mutations. Am J Med Genet. 2004;126A:272–7. [PubMed: 15054841]
  32. Du L, Damoiseaux R, Nahas S, Gao K, Hu H, Pollard JM, Goldstine J, Jung ME, Henning SM, Bertoni C, Gatti RA. Nonaminoglycoside compounds induce readthrough of nonsense mutations. J Exp Med. 2009;206:2285–97. [PMC free article: PMC2757881] [PubMed: 19770270]
  33. Du L, Gatti RA. Progress toward therapy with antisense-mediated splicing modulation. Curr Opin Mol Ther. 2009;11:116–23. [PMC free article: PMC2753608] [PubMed: 19330717]
  34. Du L, Pollard J, Gatti RA. Correction of prototypic ATM splicing mutation and aberrant ATM function with antisense morpholino oligonucleotides. PNAS. 2007;104:6007–12. [PMC free article: PMC1832221] [PubMed: 17389389]
  35. Eclache V, Caulet-Maugendre S, Poirel HA, Djemai M, Robert J, Lejeune F, Raphael M. Cryptic deletion involving the ATM locus at 11q22.3 approximately q23.1 in B-cell chronic lymphocytic leukemia and related disorders. Cancer Genet Cytogenet. 2004;152:72–6. [PubMed: 15193446]
  36. Einarsdóttir K, Rosenberg LU, Humphreys K, Bonnard C, Palmgren J, Li Y, Li Y, Chia KS, Liu ET, Hall P, Liu J, Wedren S. Comprehensive analysis of the ATM, CHEK2 and ERBB2 genes in relation to breast tumour characteristics and survival: a population-based case-control and follow-up study. Breast Cancer Res. 2006;8:R67. [PMC free article: PMC1797028] [PubMed: 17132159]
  37. Fang NY, Greiner TC, Weisenburger DD, Chan WC, Vose JM, Smith LM, Armitage JO, Mayer RA, Pike BL, Collins FS, Hacia JG. Oligonucleotide microarrays demonstrate the highest frequency of ATM mutations in the mantle cell subtype of lymphoma. Proc Natl Acad Sci U S A. 2003;100:5372–7. [PMC free article: PMC154352] [PubMed: 12697903]
  38. Farr AK, Shalev B, Crawford TO, Lederman HM, Winkelstein JA, Repka MX. Ocular manifestations of ataxia-telangiectasia. Am J Ophthalmol. 2002;134:891–6. [PubMed: 12470759]
  39. Fernandez AM, Carro EM, Lopez-Lopez C, Torres-Aleman I. Insulin-like growth factor I treatment for cerebellar ataxia: addressing a common pathway in the pathological cascade? Brain Res Brain Res Rev. 2005;50:134–41. [PubMed: 15950289]
  40. Gatti RA. Concluding discussion. In: Gatti RA, Swift M, eds. Ataxia-Telangiectasia: Genetics, Neuropathology, and Immunology of a Degenerative Disease of Childhood. New York: Alan R Liss; 1985:357-9.
  41. Gatti RA. Molecular genetics of ataxia-telangiectasia. In: de Jong JMBV, ed. Handbook of Clinical Neurology. Amsterdam: Elsevier Science Publishing; 1991:425-31.
  42. Gatti RA. Ataxia-telangiectasia. In: Vogelstein B, Kinzler KW, eds. The Genetic Basis of Human Cancer. New York: McGraw-Hill; 2002:239-65.
  43. Gatti RA, Becker-Catania S, Chun HH, Sun X, Mitui M, Lai CH, Khanlou N, Babaei M, Cheng R, Clark C, Huo Y, Udar NC, Iyer RK. The pathogenesis of ataxia-telangiectasia. Learning from a Rosetta stone. Clin Rev Allergy Immunol. 2001;20:87–108. [PubMed: 11269230]
  44. Gatti RA, Boder E, Good RA. Immunodeficiency, radiosensitivity, and the XCIND syndrome. Immunol Res. 2007;38:87–101. [PubMed: 17917014]
  45. Gatti RA, Perlman S. A proposed bailout for A-T patients? Eur J Neurol. 2009;16:653–5. [PMC free article: PMC3242728] [PubMed: 19459929]
  46. Gatti RA, Tward A, Concannon P. Cancer risk in ATM heterozygotes: a model of phenotypic and mechanistic differences between missense and trancating mutations. Molec Genet Metab. 1999;68:419–23. [PubMed: 10607471]
  47. Geoffroy-Perez B, Janin N, Ossian K, Lauge A, Croquette MF, Griscelli C, Debre M, Bressac-de-Paillerets B, Aurias A, Stoppa-Lyonnet D, Andrieu N. Cancer risk in heterozygotes for ataxia-telangiectasia. Int J Cancer. 2001;93:288–93. [PubMed: 11410879]
  48. Gilad S, Chessa L, Khosravi R, Russell P, Galanty Y, Piane M, Gatti RA, Jorensen TJ, Shiloh Y, Bar-Shira A. Genotype-phenotype relationships in ataxia-telangiectasia (A-T) and A-T variants. Am J Hum Genet. 1998;62:551–61. [PMC free article: PMC1376949] [PubMed: 9497252]
  49. Goyal V, Behari M. Dystonia as presenting manifestation of ataxia telangiectasia: a case report. Neurol India. 2002;50:187–9. [PubMed: 12134185]
  50. Hiel JA, van Engelen BG, Weemaes CM, Broeks A, Verrips A, ter Laak H, Vingerhoets HM, van den Heuvel LP, Lammens M, Gabreels FJ, Last JI, Taylor AM. Distal spinal muscular atrophy as a major feature in adult-onset ataxia telangiectasia. Neurology. 2006;67:346–9. [PubMed: 16864838]
  51. Honda M, Takagi M, Chessa L, Morio T, Mizuatni S. Rapid diagnosis of ataxia-telangiectasia by flow cytometric monitoring of DNA damage-dependent ATM phosphorylation. Leukemia. 2009;23:409–14. [PubMed: 18633429]
  52. Hu H, Gatti RA. New approaches to treatment of primary immune deficiencies: fixing mutations with chemicals. Curr Opin Allergy Clin Immunol. 2008;8:540–6. [PMC free article: PMC2686128] [PubMed: 18978469]
  53. Lagier-Tourenne C, Tazir M, Lopez LC, Quinzii CM, Assoum M, Drouot N, Busso C, Makri S, Ali-Pacha L, Benhassine T, Anheim M, Lynch DR, Thibault C, Plewniak F, Bianchetti L, Tranchant C, Poch O, DiMauro S, Mandel J-L, Barros MH, Hirano M, Koenig M. ADKC3, an ancestral kinase, is mutated in a form of recessive ataxia associated with Coenzyme Q10 deficiency. Am J Hum Genet. 2008;82:661–72. [PMC free article: PMC2427193] [PubMed: 18319074]
  54. Lai CH, Chun HH, Nahas SA, Mitui M, Gamo KM, Du L, Gatti RA. Correction of ATM gene function by aminoglycoside-induced read-through of premature termination codons. Proc Natl Acad Sci USA. 2004;101:15676–81. [PMC free article: PMC524838] [PubMed: 15498871]
  55. Larnaout A, Belal S, Ben Hamida C, Ben Hamidi L, Hentatif FI. Atypical ataxia Telangiectasia with early childhood lower motor neuron degeneration: a clinicopathological observation in three siblings. J Neurol. 1998;245:231–5. [PubMed: 9591225]
  56. Lavin MF. Ataxia-telangiectasia: from a rare disorder to a paradigm for cell signalling and cancer. Nat Rev Mol Cell Biol. 2008;9:759–69. [PubMed: 18813293]
  57. Lavin MF, Concannon P, Gatti RA. Eighth International Workshop on Ataxia-Telangiectasia (ATW8). Cancer Res. 1999;59:3845–9. [PubMed: 10447004]
  58. Lefton-Greif MA, Crawford TO, Winkelstein JA, Loughlin GM, Koerner CB, Zahurak M, Lederman HM. Oropharyngeal dysphagia and aspiration in patients with ataxia-telangiectasia. J Pediatr. 2000;136:225–31. [PubMed: 10657830]
  59. Lewis RF, Lederman HM, Crawford TO. Ocular motor abnormalities in ataxia telangiectasia. Ann Neurol. 1999;46:287–95. [PubMed: 10482258]
  60. Liberzon E, Avigad S, Stark B, Zilberstein J, Freedman L, Gorfine M, Gavriel H, Cohen IJ, Goshen Y, Yaniv I, Zaizov R. Germ-line ATM gene alterations are associated with susceptibility to sporadic T-cell acute lymphoblastic leukemia in children. Genes Chromosomes Cancer. 2004;39:161–6. [PubMed: 14695997]
  61. Lin DD, Crawford TO, Lederman HM, Barker PB. Proton MR spectroscopic imaging in ataxia-telangiectasia. Neuropediatrics. 2006;37:241–6. [PubMed: 17177151]
  62. Linding R, Jensen LJ, Ostheimer GJ, van Vugt MA, Jørgensen C, Miron IM, Diella F, Colwill K, Taylor L, Elder K, Metalnikov P, Nguyen V, Pasculescu A, Jin J, Park JG, Samson LD, Woodgett JR, Russell RB, Bork P, Yaffe MB, Pawson T. Systematic discovery of in vivo phosphorylation networks. Cell. 2007;129:1415–26. [PMC free article: PMC2692296] [PubMed: 17570479]
  63. Matsuoka S, Ballif BA, Smogorzewska A, McDonald ER 3rd, Hurov KE, Luo J, Bakalarski CE, Zhao Z, Solimini N, Lerenthal Y, Shiloh Y, Gygi SP, Elledge SJ. ATM and ATR substrate analysis reveals extensive protein networks responsive to DNA damage. Science. 2007;316:1160–6. [PubMed: 17525332]
  64. McConville CM, Stankovic T, Byrd PJ, McGuire GM, Yao QY, Lennox GG, Taylor MR. Mutations associated with variant phenotypes in ataxia-telangiectasia. Am J Hum Genet. 1996;59:320–30. [PMC free article: PMC1914715] [PubMed: 8755918]
  65. McGrath-Morrow S, Lefton-Greif M, Rosquist K, Crawford T, Kelly A, Zeitlin P, Carson KA, Lederman HM. Pulmonary function in adolescents with ataxia telangiectasia. Pediatr Pulmonol. 2008;43:59–66. [PubMed: 18041755]
  66. Mitui M, Bernatowska E, Pietrucha B, Piotrowska-Jastrzebska J, Eng L, Nahas S, Teraoka S, Sholty G, Purayidom A, Concannon P, Gatti RA. ATM gene founder haplotypes and associated mutations in Polish families with ataxia-telangiectasia. Ann Hum Genet. 2005;69:657–64. [PubMed: 16266405]
  67. Mitui M, Campbell C, Coutinho G, Sun X, Lai CH, Thorstenson Y, Castellvi-Bel S, Fernandez L, Monros E, Carvalho BT, Porras O, Fontan G, Gatti RA. Independent mutational events are rare in the ATM gene: haplotype prescreening enhances mutation detection rate. Hum Mutat. 2003;22:43–50. [PubMed: 12815592]
  68. Mitui M, Nahas SA, Du LT, Yang Z, Lai CH, Nakamura K, Arroyo S, Scott S, Purayidom A, Concannon P, Lavin M, Gatti RA. Functional and computational assessment of missense variants in the ATM gene: mutations with increased cancer risk. Hum Mutat. 2009;30:12–21. [PMC free article: PMC2776735] [PubMed: 18634022]
  69. Moreira MC, Barbot C, Tachi N, Kozuka N, Uchida E, Gibson T, Mendonca P, Costa M, Barros J, Yanagisawa T, Watanabe M, Ikeda Y, Aoki M, Nagata T, Coutinho P, Sequeiros J, Koenig M. The gene mutated in ataxia-ocular apraxia 1 encodes the new HIT/Zn- finger protein aprataxin. Nat Genet. 2001;29:189–93. [PubMed: 11586300]
  70. Moreira MC, Klur S, Watanabe M, Németh AH, Le Ber I, Moniz JC, Tranchant C, Aubourg P, Tazir M, Schols L, Pandolfo M, Schulz JB, Pouget J, Calvas P, Shizuka-Ikeda M, Shoji M, Tanaka M, Izatt L, Shaw CE, M'Zahem A, Dunne E, Bomont P, Benhassine T, Bouslam N, Stevanin G, Brice A, Guimaraes J, Mendonca P, Barbot C, Coutinho P, Sequeiros J, Durr A, Warter JM, Koenig M. Senataxin, the ortholog of a yeast RNA helicase, is mutant in ataxia-ocular apraxia 2. Nat Genet. 2004;36:225–7. [PubMed: 14770181]
  71. Nahas SA, Butch AW, Du LT, Gatti RA. Rapid flow cytometry-based SMC1 phosphorylation assay for identification of ataxia-telangiectasia homozygotes and heterozygotes. Clin Chem. 2009;55:463–72. [PMC free article: PMC2980758] [PubMed: 19147735]
  72. Nahas SA, Duquette A, Roddier K, Gatti RA, Brais B. Ataxia-oculomotor apraxia 2 (AOA2) patients show no increased sensitivity to ionizing radiation. Neuromuscul Disord. 2007;17:968–9. [PubMed: 17720498]
  73. Nahas SA, Lai CH, Gatti RA. Post-irradiation phosphorylation of structural maintenance chromosome 1 (SMC1) is independent of the Fanconi protein pathway. Int J Radiat Oncol Biol Phys. 2005;61:1167–72. [PubMed: 15752898]
  74. Németh AH, Bochukova E, Dunne E, Huson SM, Elston J, Hannan MA, Jackson M, Chapman CJ, Taylor AM. Autosomal recessive cerebellar ataxia with oculomotor apraxia (ataxia-telangiectasia-like syndrome) is linked to chromosome 9q34. Am J Hum Genet. 2000;67:1320–6. [PMC free article: PMC1288574] [PubMed: 11022012]
  75. Nowak-Wegrzyn A, Crawford TO, Winkelstein JA, Carson KA, Lederman HM. Immunodeficiency and infections in ataxia-telangiectasia. J Pediatr. 2004;144:505–11. [PubMed: 15069401]
  76. O'Driscoll M, Cerosaletti KM, Girard PM, Dai Y, Stumm M, Kysela B, Hirsch B, Gennery A, Palmer SE, Seidel J, Gatti RA, Varon R, Oettinger MA, Neitzel H, Jeggo PA, Concannon P. DNA ligase IV mutations identified in patients exhibiting developmental delay and immunodeficiency. Mol Cell. 2001;8:1175–85. [PubMed: 11779494]
  77. Oguchi K, Takagi M, Tsuchida R, Taya Y, Ito E, Isoyama K, Ishii E, Zannini L, Delia D, Mizutani S. Missense mutation and defective function of ATM in a childhood acute leukemia patient with MLL gene rearrangement. Blood. 2003;101:3622–7. [PubMed: 12511424]
  78. Olsen JH, Hahnemann JM, Borresen-Dale AL, Brondum-Nielsen K, Hammarstrom L, Kleinerman R, Kaariainen H, Lonnqvist T, Sankila R, Seersholm N, Tretli S, Yuen J, Boice JD Jr, Tucker M. Cancer in patients with ataxia-telangiectasia and in their relatives in the nordic countries. J Natl Cancer Inst. 2001;93:121–7. [PubMed: 11208881]
  79. Onodera O. Spinocerebellar ataxia with ocular motor apraxia and DNA repair. Neuropathology. 2006;26:361–7. [PubMed: 16961074]
  80. Pashankar F, Singhal V, Akabogu I, Gatti RA, Goldman FD. Intact T cell responses in ataxia telangiectasia. Clin Immunol. 2006;120:156–62. [PubMed: 16762595]
  81. Perlman S, Becker-Catania S, Gatti RA. Ataxia-telangiectasia: diagnosis and treatment. Semin Pediatr Neurol. 2003;10:173–82. [PubMed: 14653405]
  82. Pitts SA, Kullar HS, Stankovic T, Stewart GS, Last JI, Bedenham T, Armstrong SJ, Piane M, Chessa L, Taylor AM, Byrd PJ. hMRE11: genomic structure and a null mutation identified in a transcript protected from nonsense-mediated mRNA decay. Hum Mol Genet. 2001;10:1155–62. [PubMed: 11371508]
  83. Pollard JM, Reboucas JS, Durazo A, Kos I, Fike F, Panni M, Gralla EB, Valentine JS, Batinic-Haberle I, Gatti RA. Radioprotective effects of manganese-containing superoxide dismutase mimics on ataxia-telangiectasia cells. Free Radic Biol Med. 2009;47:250–60. [PMC free article: PMC3592562] [PubMed: 19389472]
  84. Porcedda P, Turinetto V, Brusco A, Cavalieri S, Lantelme E, Orlando L, Ricardi U, Amoroso A, Gregori D, Giachino C. A rapid flow cytometry test based on histone H2AX phosphorylation for the sensitive and specific diagnosis of ataxia telangiectasia. Cytometry A. 2008;73:508–16. [PubMed: 18431795]
  85. Pylkäs K, Tommiska J, Syrjäkoski K, Kere J, Gatei M, Waddell N, Allinen M, Karppinen SM, Rapakko K, Kääriäinen H, Aittomäki K, Blomqvist C, Mustonen A, Holli K, Khanna KK, Kallioniemi OP, Nevanlinna H, Winqvist R. Evaluation of the role of Finnish ataxia-telangiectasia mutations in hereditary predisposition to breast cancer. Carcinogenesis. 2007;28:1040–5. [PubMed: 17166884]
  86. Reliene R, Schiestl RH. Antioxidant N-acetyl cysteine reduces incidence and multiplicity of lymphoma in Atm deficient mice. DNA Repair. 2006;5:852–9. [PubMed: 16781197]
  87. Renwick A, Thompson D, Seal S, Kelly P, Chagtai T, Ahmed M, North B, Jayatilake H, Barfoot R, Spanova K, McGuffog L, Evans DG, Eccles D. Breast Cancer Susceptibiltiy Collaboration (UK), Easton DF, Stratton MR, Rahman N. ATM mutations that cause ataxia-telangiectasia are breast cancer suceptibiltity alleles. Nat Genet. 2006;38:873–5. [PubMed: 16832357]
  88. Richards CS, Bale S, Bellissimo DB, Das S, Grody WW, Hegde MR, Lyon E, Ward BE. Molecular Subcommittee of the ACMG Laboratory Quality Assurance Committee. ACMG recommendations for standards for interpretation and reporting of sequence variations: Revisions 2007. Genet Med. 2008;10:294–300. [PubMed: 18414213]
  89. Sanal O, Ersoy F, Yel L, Tezcan I, Metin A, Ozyurek H, Gariboglu S, Fikrig S, Berkel AI, Rijkers GT, Zegers BJ. Impaired IgG antibody production to pneumococcal polysaccharides in patients with ataxia-telangiectasia. J Clin Immunol. 1999;19:326–34. [PubMed: 10535610]
  90. Sardanelli F, Parodi RC, Ottonello C, Renzetti P, Saitta S, Lignana E, Mancardi GL. Cranial MRI in ataxia-telangiectasia. Neuroradiology. 1995;37:77–82. [PubMed: 7708196]
  91. Saunders-Pullman RJ, Gatti R. Ataxia-telangiectasia: without ataxia or telangiectasia? Neurology. 2009;73:414–5. [PubMed: 19605768]
  92. Saviozzi S, Saluto A, Taylor AM, Last JI, Trebini F, Paradiso MC, Grosso E, Funaro A, Ponzio G, Migone N, Brusco A. A late onset variant of ataxia-telangiectasia with a compound heterozygous genotype, A8030G/7481insA. J Med Genet. 2002;39:57–61. [PMC free article: PMC1734960] [PubMed: 11826028]
  93. Scott SP, Bendix R, Chen P, Clark R, Dörk T, Lavin MF. Missense mutations but not allelic variants alter the function of ATM by dominant interference in patients with breast cancer. Proc Natl Acad Sci U S A. 2002;99:925–30. [PMC free article: PMC117407] [PubMed: 11805335]
  94. Shackelford RE, Manuszak RP, Johnson CD, Hellrung DJ, Link CJ, Wang S. Iron chelators increase the resistance of Ataxia telangeictasia cells to oxidative stress. DNA Repair (Amst) 2004;3:1263–72. [PubMed: 15336622]
  95. Sommer SS, Buzin CH, Jung M, Zheng J, Liu Q, Jeong SJ, Moulds J, Nguyen VQ, Feng J, Bennett WP, Dritschilo A. Elevated frequency of ATM gene missense mutations in breast cancer relative to ethnically matched controls. Cancer Genet Cytogenet. 2002;134:25–32. [PubMed: 11996792]
  96. Sommer SS, Jiang Z, Feng J, Buzin CH, Zheng J, Longmate J, Jung M, Moulds J, Dritschilo A. ATM missense mutations are frequent in patients with breast cancer. Cancer Genet Cytogenet. 2003;145:115–20. [PubMed: 12935922]
  97. Spring K, Ahangari F, Scott SP, Waring P, Purdie DM, Chen PC, Hourigan K, Ramsay J, McKinnon PJ, Swift M, Lavin MF. Mice heterozygous for mutation in Atm, the gene involved in ataxia- telangiectasia, have heightened susceptibility to cancer. Nat Genet. 2002;32:185–90. [PubMed: 12195425]
  98. Stankovic T, Kidd AM, Sutcliffe A, McGuire GM, Robinson P, Weber P, Bedenham T, Bradwell AR, Easton DF, Lennox GG, Haites N, Byrd PJ, Taylor AM. ATM mutations and phenotypes in ataxia-telangiectasia families in the British Isles: expression of mutant ATM and the risk of leukemia, lymphoma, and breast cancer. Am J Hum Genet. 1998;62:334–45. [PMC free article: PMC1376883] [PubMed: 9463314]
  99. Stewart GS, Last J.I., Stankovic T., Haites N., Kidd A.M., Byrd P.J., Taylor A.M. Residual ataxia telangiectasia mutated protein function in cells from ataxia telangiectasia patients, with 5762ins137 and 7271T-->G mutations, showing a less severe phenotype. J Biol Chem. 2001;276:30133–41. [PubMed: 11382771]
  100. Stewart GS, Maser RS, Stankovic T, Bressan DA, Kaplan MI, Jaspers NG, Raams A, Byrd PJ, Petrini JH, Taylor AM. The DNA double-strand break repair gene hMRE11 is mutated in individuals with an ataxia-telangiectasia-like disorder. Cell. 1999;99:577–87. [PubMed: 10612394]
  101. Stewart GS, Panier S, Townsend K, Al-Hakim AK, Kolas NK, Miller ES, Nakada S, Ylanko J, Olivarius S, Mendez M, Oldreive C, Wildenhain J, Tagliaferro A, Pelletier L, Taubenheim N, Durandy A, Byrd PJ, Stankovic T, Taylor AM, Durocher D. The RIDDLE syndrome protein mediates a ubiquitin-dependent signaling cascade at sites of DNA damage. Cell. 2009;136:420–34. [PubMed: 19203578]
  102. Stewart GS, Stankovic T, Byrd PJ, Wechsler T, Miller ES, Huissoon A, Drayson MT, West SC, Elledge SJ, Taylor AM. RIDDLE immunodeficiency syndrome is linked to defects in 53BP1-mediated DNA damage signaling. Proc Natl Acad Sci U S A. 2007;104:16910–5. [PMC free article: PMC2040433] [PubMed: 17940005]
  103. Stilgenbauer S, Schaffner C, Winkler D, Ott G, Leupolt E, Bentz M, Moller P, Muller-Hermelink HK, James MR, Lichter P, Dohner H. The ATM gene in the pathogenesis of mantle-cell lymphoma. Ann Oncol. 2000;11 Suppl 1:127–30. [PubMed: 10707794]
  104. Sun X, Becker-Catania SG, Chun HH, Hwang MJ, Huo Y, Wang Z, Mitui M, Sanal O, Chessa L, Crandall B, Gatti RA. Early diagnosis of ataxia-telangiectasia using radiosensitivity testing. J Pediatr. 2002;140:724–31. [PubMed: 12072877]
  105. Sutton IJ, Last JIK, Richie SJ, Harrington HJ, Byrd PH, Taylor AMR. Adult-onset ataxia telangiectasia due to ATM 5762ins137 mutation homozygosity. Ann Neurol. 2004;55:891–5. [PubMed: 15174027]
  106. Swift M. Genetics and epidemiology of ataxia-telangiectasia. In: Gatti RA, Swift M, eds. Ataxia-Telangiectasia: Genetics, Neuropathology, and Immunology of a Degenerative Disease of Childhood. New York: Alan R Liss; 1985:133-44.
  107. Swift M, Morrell D, Massey RB, Chase CL. Incidence of cancer in 161 families affected by ataxia-telangiectasia. N Engl J Med. 1991;325:1831–6. [PubMed: 1961222]
  108. Tangsinmankong N, Wayne AS, Howenstine MS, Washington KR, Langston C, Gatti RA, Good RA, Nelson RP Jr. Lymphocytic interstitial pneumonitis, elevated IgM concentration, and hepatosplenomegaly in ataxia-telangiectasia. J Pediatr. 2001;138:939–41. [PubMed: 11391347]
  109. Tavani F, Zimmerman RA, Gerry GT, Sullivan K, Gatti R, Bingham P. Ataxia-telangiectasia: the pattern of cerebellar atrophy on MRI. Neuroradiology. 2003;45:315–9. [PubMed: 12740724]
  110. Tavtigian SV, Oefner PJ, Babikyan D, Hartmann A, Healey S, Le Calvez-Kelm F, Lesueur F, Byrnes GB, Chuang SC, Forey N, Feuchtinger C, Gioia L, Hall J, Hashibe M, Herte B, McKay-Chopin S, Thomas A, Vallée MP, Voegele C, Webb PM, Whiteman DC., Australian Cancer Study. Breast Cancer Family Registries (BCFR); Kathleen Cuningham Foundation Consortium for Research into Familial Aspects of Breast Cancer (kConFab), Sangrajrang S, Hopper JL, Southey MC, Andrulis IL, John EM, Chenevix-Trench G2009Rare, evolutionarily unlikely missense substitutions in ATM confer increased risk of breast cancer. Am J Hum Genet. 85427–46. [PMC free article: PMC2756555] [PubMed: 19781682]
  111. Taylor AM, Byrd PJ. Molecular pathology of ataxia telangiectasia. J Clin Pathol. 2005;58:1009–15. [PMC free article: PMC1770730] [PubMed: 16189143]
  112. Teraoka SN, Malone KE, Doody DR, Suter NM, Ostrander EA, Daling JR, Concannon P. Increased frequency of ATM mutations in breast carcinoma patients with early onset disease and positive family history. Cancer. 2001;92:479–87. [PubMed: 11505391]
  113. Thorstenson YR, Roxas A, Kroiss R, Jenkins MA, Yu KM, Bachrich T, Muhr D, Wayne TL, Chu G, Davis RW, Wagner TM, Oefner PJ. Contributions of ATM mutations to familial breast and ovarian cancer. Cancer Res. 2003;63:3325–33. [PubMed: 12810666]
  114. Trimis GG, Athanassaki CK, Kanariou MM, Giannoulia-Karantana AA. Unusual absence of neurologic symptoms in a six-year old girl with ataxia-telangiectasia. J Postgrad Med. 2004;50:270–1. [PubMed: 15623968]
  115. van der Burg M, Ijspeert H, Verkaik NS, Turul T, Wiegant WW, Morotomi-Yano K, Mari PO, Tezcan I, Chen DJ, Zdzienicka MZ, van Dongen JJ, van Gent DC. A DNA-PKcs mutation in a radiosensitive T-B- SCID patient inhibits Artemis activation and nonhomologous end-joining. J Clin Invest. 2009;119:91–8. [PMC free article: PMC2613452] [PubMed: 19075392]
  116. Verhagen MM, Abdo WF, Willemsen MA, Hogervorst FB, Smeets DF, Hiel JA, Brunt ER, van Rijn MA, Majoor Krakauer D, Oldenburg RA, Broeks A, Last JI, van't Veer LJ, Tijssen MA, Dubois AM, Kremer HP, Weemaes CM, Taylor AM, van Deuren M. Clinical spectrum of ataxia-telangiectasia in adulthood. Neurology. 2009;73:430–7. [PubMed: 19535770]
  117. Wallis LI, Griffiths PD, Ritchie SJ, Romanowski CA, Darwent G, Wilkinson ID. Proton spectroscopy and imaging at 3T in ataxia-telangiectasia. AJNR Am J Neuroradiol. 2007;28:79–83. [PubMed: 17213429]
  118. Waltes R, Kalb R, Gatei M, Kijas AW, Stumm M, Sobeck A, Wieland B, Varon R, Lerenthal Y, Lavin MF, Schindler D, Dörk T. Human RAD50 deficiency in a Nijmegen breakage syndrome-like disorder. Am J Hum Genet. 2009;84:605–16. [PMC free article: PMC2681000] [PubMed: 19409520]
  119. Welch EM, Barton ER, Zhuo J, Tomizawa Y, Friesen WJ, Trifillis P, Paushkin S, Patel M, Trotta CR, Hwang S, Wilde RG, Karp G, Takasugi J, Chen G, Jones S, Ren H, Moon YC, Corson D, Turpoff AA, Campbell JA, Conn MM, Khan A, Almstead NG, Hedrick J, Mollin A, Risher N, Weetall M, Yeh S, Branstrom AA, Colacino JM, Babiak J, Ju WD, Hirawat S, Northcutt VJ, Miller LL, Spatrick P, He F, Kawana M, Feng H, Jacobson A, Peltz SW, Sweeney HL. PTC124 targets genetic disorders caused by nonsense mutations. Nature. 2007;447:87–91. [PubMed: 17450125]
  120. Wilschanski M, Yahav Y, Yaacov Y, Blau H, Bentur L, Rivlin J, Aviram M, Bdolah-Abram T, Bebok Z, Shushi L, Kerem B, Kerem E. Gentamicin-induced correction of CFTR function in patients with cystic fibrosis and CFTR stop mutations. N Engl J Med. 2003;349:1433–41. [PubMed: 14534336]
  121. Woods CG, Taylor AM. Ataxia telangiectasia in the British Isles: the clinical and laboratory features of 70 affected individuals. Q J Med. 1992;82:169–79. [PubMed: 1377828]
  122. Yakusheva TA, Shaikh AG, Green AM, Blazquez PM, Dickman JD, Angelaki DE. Purkinje cells in posterior cerebellar vermis encode motion in an inertial reference frame. Neuron. 2007;54:973–85. [PubMed: 17582336]
  123. Yamaguchi M, Yamamoto K, Miki T, Mizutani S, Miura O. T-cell prolymphocytic leukemia with der(11)t(1;11)(q21;q23) and ATM deficiency. Cancer Genet Cytogenet. 2003;146:22–6. [PubMed: 14499692]
  124. Yanofsky RA, Seshia SS, Dawson AJ, Stobart K, Greenberg CR, Booth FA, Prasad C, Del Bigio MR, Wrogemann JJ, Fike F, Gatti RA. Ataxia-telangiectasia: atypical presentation and toxicity of cancer treatment. Can J Neurol Sci. 2009;36:462–7. [PubMed: 19650357]

Suggested Reading

  1. Uhrhammer N, Bay JO, Perlman S, Gatti RA. Ataxia telangiectasia and variants. Atlas of Genetics and Cytogenetics in Oncology and Haematology. Available online. 2002. Accessed 10-19-15.

Chapter Notes

Revision History

  • 11 March 2010 (me) Comprehensive update posted live
  • 15 February 2005 (me) Comprehensive update posted to live Web site
  • 10 April 2003 (cd) Revision: sequence analysis available
  • 8 October 2002 (me) Comprehensive update posted to live Web site
  • 19 March 1999 (pb) Review posted to live Web site
  • 13 April 1998 (rg) Original submission
Copyright © 1993-2016, University of Washington, Seattle. All rights reserved.

For more information, see the GeneReviews Copyright Notice and Usage Disclaimer.

For questions regarding permissions: ude.wu@tssamda.

Bookshelf ID: NBK26468PMID: 20301790


Tests in GTR by Condition

Related information

  • MedGen
    Related information in MedGen
  • OMIM
    Related OMIM records
  • PMC
    PubMed Central citations
  • PubMed
    Links to PubMed
  • Gene
    Locus Links

Similar articles in PubMed

See reviews...See all...

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...